DENVER - Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Wednesday, July 21, 2010, at 4:00 PM EDT to discuss the Company’s announced major collaboration and investment from the ELITech Group, a Paris, France-based, privately held group of companies and worldwide manufacturer and distributor of in-vitro diagnostic equipment and reagents. The Form 8-K related to this transaction has been filed with the Securities and Exchange Commission today, July 16, 2010, and will be followed by a press release next Monday, July 19, 2010.

Corgenix invites all those interested in hearing management’s discussion to join the call by dialing:

U.S. attendees: (800) 894-5910
International attendees: +1 785 424 1052
Conference code is: CORGENIX

A question-and-answer session will follow the presentation by Corgenix management.

A replay will be available for 30 days following the call by dialing (800) 839-2382 for U.S. participants and +1 402 220 7201 for international participants.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.

Company Contact:
Corgenix Medical Corp
William Critchfield, Senior VP and CFO
Phone (303) 453-8903
Email: wcritchfield@corgenix.com

Media Contact:
Armada Medical Marketing
Dan Snyders, Vice President, Public Relations Supervisor
Phone: 303-623-1190 x 230
Email: dan@armadamedical.com